Novartis Gene Therapy Production Durham, North Carolina

Our new 14TW site in Durham, North Carolina is one of three sites that make up our Flagship Manufacturing Hub. The hub will enable end-to-end  manufacturing for treatments across oncology, immunology, neuroscience, and cardiovascular, renal and metabolic diseases. 

Once completed, this site will include two facilities dedicated to manufacturing biologics and sterile packaging. This includes a large-scale cell culture facility and a packaging unit.  

Key Facts About the Site

2028
site expected to open
1 of 3
sites that comprise our

North Carolina Manufacturing Hub

~270K
square-foot site

See Photos from Across Our North Carolina Flagship Manufacturing Hub

Learn more about our recent groundbreaking in Durham, North Carolina, as well as our “Wall of Hands” at our gene therapy manufacturing facility: For every dose of gene therapy produced and shipped, a “handprint” is placed on the wall. Read the full story here.  

  • Team shot at the groundbreaking, with shovels in sand. View
    1/5
  • Novartis CEO, Vas Narasimhan, and attendees at the groundbreaking of a North Carolina manufacturing site View
    2/5
  • 3 members of the Novartis team touring the groundbreaking site. View
    3/5
  • A bulldozer on the groundbreaking site. View
    4/5
  • The “Wall of Hands” at our gene therapy manufacturing facility in Durham, NC. The paper hand prints represent doses of medicine shipped to patients. View
    5/5
scientists fist bumping

Explore Career Opportunities in Durham

From science roles to manufacturing to business, find the right role at Novartis in the US and join us as we work to reimagine medicine.

Learn More

Featured Stories

Team shot at the groundbreaking, with shovels in sand.

Building for the Future: Novartis Expands Manufacturing Hub in North Carolina

The creation of a 700,000-square-foot flagship manufacturing hub marks the continuation of our investment in the US, enabling us to more reliably reach patients across the country.
2 2001 Aerial photo-d

Novartis in San Diego: A Quarter Century of R&D Innovation

A look back at a legacy of biomedical research breakthroughs that trace their roots to our San Diego site.
A Novartis employee and Veteran, Matt Baca, featured during his time in the military.

How This Former Army Officer Helps Deliver Cancer Treatments to Patients, Through Hurricanes and Beyond

Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.

Latest News

Dec 12, 2025

  • Media Release

Novartis breaks ground on flagship manufacturing hub in North Carolina

Nov 19, 2025

  • Media Release

Novartis announces plans to build flagship manufacturing hub in North Carolina

Apr 10, 2025

  • Media Release

Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
View More

See Our Other US Sites

Novartis Radioligand Therapy Production Carlsbad California

Carlsbad, CA

Our third US radioligand therapy manufacturing site opened in 2025 and serves patients across the western US, Alaska and Hawaii.
Novartis radioligand therapy site under construction in Indianapolis

Indianapolis, IN

Our second US radioligand therapy manufacturing site opened in 2024. Expansion of the site is ongoing.
Novartis Cell Therapy Production Morris Plains New Jersey

Morris Plains, NJ

Since 2015, the site has specialized in the production of groundbreaking cell therapies.
Scientist working in a laboratory with test tubes and scientific equipment

Denton, TX

Expected to become fully operational in 2028, our fifth US radioligand manufacturing site will serve patients in the southern US.
Novartis Gene Therapy Production Durham North Carolina

Durham, NC (TriCenter)

The site produces innovative gene therapies and is expanding to support sterile filling of biologics into syringes and vials. 
Morrisville, North Carolina

Morrisville, NC

Two new facilities for production and packaging of small molecule medicines, and active pharmaceutical ingredient manufacturing.
Novartis Radioligand Therapy Production Millburn New Jersey

Millburn, NJ

Our first US radioligand therapy manufacturing site opened in 2023. Its on-site production capabilities continue to expand.
Biomedical Research organization in Cambridge, Massachusetts

Cambridge, MA

This Biomedical Research organization, established in 2003, is dedicated to scientific innovation and drug discovery.
radioligand therapy manufacturing facility in Winter Park, Florida

Winter Park, FL

Expected to open in 2029, our fourth US radioligand manufacturing site will optimize delivery for patients across the southeastern US.
Novartis Biomedical Research Center in San Diego, California

San Diego, CA

In 2026, we broke ground on a new global Biomedical Research center designed to accelerate drug discovery.

Learn More About Our Investment in the US

Return to Investing in America’s Health